Abstract. The increased knowledge regarding HPV-infections in head and neck squamous cell carcinoma (HNSCC) has unexpectedly contributed to several uncertainties related to i) prevalence diversities depending on tumour site and geographical origin of the patients, ii) proportion of HPV-driven tumours among HPV-DNA-positive cases, and iii) identification of patients with HPV-attributed survival benefit. To investigate this heterogeneity, we analysed 307 HNSCC cases (tonsillar, n=135; non-tonsillar, n=172) from eight health care centers mostly from Northern Germany and determined HPV-DNA/mRNA and p16
Introduction
Human papillomavirus (HPV) infection is an important feature causing a specific subset of head and neck squamous cell carcinoma (HNSCC). Specifically SCC of the palatine and lingual tonsils, located in the anatomical region of the oropharynx, are connected to infections with predominantly HPV genotype 16 (1) (2) (3) (4) . HPV positive HNSCC are con sidered a tumour entity with patients being younger, male, Caucasians, and showing overall and recurrence-free survival rates superior to those of HPV negative patients (1, 5, 6) . The latter most likely is true for cases with active HPV infections, characterized by mRNA expression of the viral e6/e7 proteins as direct marker or, in consequence of a negative feedback regulation to E7 activity, p16 INK4A over expression as indirect marker (7) (8) (9) (10) (11) (12) . HNSCC harbouring active HPV infections are considered to be truly HPV-driven (7) . The impressive survival advantage of cases positive for active HPV infections have been demonstrated in diverse populations worldwide (1, 2, 5, 13) . This prompted clinicians to consider modifications of established treatment regimens, specifically radiotherapy regimes since survival advantages have repeatedly been attributed to higher radiosensitivity of HPV positive cases. De-intensification of radiotherapy applied to patients with HPV-driven HNSCC consecutively minimizing treatment morbidity is momentarily discussed as the HPV-dependent treatment option (14) .
Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany
It is important to keep in mind that the majority of HPV positive patients receive (adjuvant) radio(chemo)therapy for the following reason: at first time presentation, patients with HPV-positive HNSCC regularly show higher disease burden, specifically higher lymph nodal masses in the lateral neck (15, 16) , assigning these patients for treatment strategies including radiotherapy. Thus, unaware of the HPV status the majority of patients with actually HPV-driven tumours receive the most promising treatment regime exclusively based on their clinical tumour characteristics.
There is an increasing amount of studies reporting on diverging HPV prevalence rates (0-90%) throughout the world (3) (4) (5) 13, (17) (18) (19) . Discordant recommendations how to identify true HPV-driven cancers and, thereby cases with the best prognosis, namely by either i) viral mRNA detection or by ii) p16
INK4A
immunohistochemistry performed additionally to HPV DNA detection, by iii) a combination of both or even other parameters or iv) determination of HPV related methylation signatures, and v) in situ hybridization techniques (5, (7) (8) (9) 11, 13, (20) (21) (22) (23) do hamper the routine diagnosis of HPV status in HNSCC patients and cause uncertainties among clinicians. Additionally, there is increasing data describing a subgroup of patients showing p16 INK4A overexpression, yet, either being completely HPV negative or HPV DNA-positive but HPV mRNA-negative, thus, not bearing HPV-driven tumours (9, 24) .
In the present study, we determined the HPV infection status of HNSCC from 307 patients with tonsillar and nontonsillar tumours collected from eight health care centres mostly from Northern Germany and investigated HPV DNA-, E6/E7 mRNA presence and p16
INK4A expression in the tumour specimens in a single laboratory setting. The aim of the study was to i) determine the prevalence rate of active HPV infections comparing tonsillar and non-tonsillar tumours, ii) investigate possible geographical influences on prevalence rates, iii) identify parameters or combinations of parameters of highest prognostic value, and iv) specifically focus on the subgroup of patients with HPV-independent p16 INK4A overexpression. Participating centres were located in Rostock, Greifswald, Kiel, Lübeck, Hanover, Oldenburg, Hamburg, and Cologne (see Fig. 1 ). All patients were Caucasians and had no migration background. For further analysis with the aim to increase case numbers cases from i) Rostock and Greifswald and ii) Kiel and Lübeck were investigated as one group, respectively (each grouping was based on comparability of city characteristics in terms of infrastructure, population and geographic location rather than geographical distance). Details of participating centres can be found in the list of affiliations. Number of cases contributed and first results regarding HPV-status and tumour localisation are listed in Table I .
Materials and methods

Patients
The anatomical location of all analysed primary tumours was as follows: tonsils [(n=135) palatine tonsil (n=87); lingual tonsil (n=48)], larynx (n=55), hypopharynx (n=38), oral cavity (n=59), and oropharynx [other than tonsil (n=20)]. It is important to note that the centres were asked to contribute similar numbers of tonsillar and non-tonsillar cases. Therefore, case numbers do not reflect distribution of tumour entities of the various centres. In the following tonsillar cases (n=135) and non-tonsillar cases (n=172) were summarized for further molecular and statistical analysis.
Nucleic acid extraction, HPV detection, cDNA synthesis and qPCR. DNA was extracted using depending on tumour size tissue 4-6 consecutive 10-µm sections derived from formalin-fixed paraffin-embedded (FFPe) tissue specimens. DNA extraction and HPV detection was performed, as previously described (9, 25) .
For RNA extraction 5 consecutive 10 µm sections from the above tissue specimens were used. RNA was isolated using the FFPE RNAready kit (AmpTec, Hamburg, Germany) according to the manufacturer's protocol. cDNA synthesis and. qPCR was performed as previously described (26) . e6/e7 primers are described elsewhere (27) .
Immunohistochemistry for p16
INK4A . FFPE tissue specimens (2-µm sections) were stained for p16
INK4A expression as previously described (8) . Immunostaining was evaluated according to Klaes and coworkers (28) . Depending on these criteria (28) the results were classified as negative (-), weak (+), moderate (++), and strong (+++), respectively.
Statistical analyses. From four of the initially recruited 311
FFPe samples, no DNA could be isolated. These blocks and respective patient information were dismissed from further analysis. Statistical analysis was performed for 280/307 patients; 27 patients were lost to follow-up (n=17) or patient files were incomplete (n=10). median follow-up was 2.3 years (range, 2.1 to 12.14 years). For survival analysis according to Kaplanmeier, primary statistical endpoints were progression-free survival (PFS) and overall survival (OS). PFS and OS were defined as time from first diagnosis to date of disease progression and last follow-up examination or death, respectively. Factors tested for prognostic value included, smoking habit, tumour size (T, according to the TNm Classification of the uICC 1992), incidence and extent of lymph node metastasis (N, according to the TNm Classification of the uICC 1992), location of the primary tumour, HPV DNA and mRNA status, and p16
INK4A expression in the tissue samples. log-rank test was used to test for significant differences between the groups. Fisher's exact test was used relating HPV positivity to p16 INK4A and e6/e7 mRNA expression. p-values ≤0.05 were accepted as statistically significant.
Results
HPV DNA analysis. HPV DNA analysis was performed in 307 tumour specimens derived from tonsillar (n=135) and nontonsillar (n=172) SCC patients.
Out of these 307 investigated patients, 72 (23.5%) showed HPV DNA with an HPV prevalence rate of 43.7% (59/135) and 7.6% (13/172) in tonsillar and non-tonsillar cases, respectively. In non-tonsillar SCC, HPV DNA could be detected in SCC of the larynx, 5/55 (9.1%); the hypopharynx, 2/38 (5.2%); the oropharynx other than tonsil, 3/20 (15%); and the oral cavity, 3/59 (5.1%). The HPV genotypes detected were HPV16, HPV18, HPV26 and HPV31 in 68, two, and one case each, respectively (Table II) . except for HPV26, which was identified in a tonsillar SCC, all other non-HPV16-types were found in laryngeal SCC.
At first time diagnosis patients with HPV DNA-positive and HPV DNA-negative tumours showed no differences in age (p>0.05); the same was true for HPV RNA. moreover, the distribution of cases with T1/T2 and T3/T4 primary tumours was equall among HPV positive and negative patients whereas HPV-positive cases showed significantly higher lymph nodedisease status compared to HPV-negative patients (p= 0.015; data not shown). Among HPV DNA positive cases, the number of smokers and non-smokers were approximately the same, whereas among HPV DNA-negative cases there were significantly more smokers than non-smokers (p<0.001, data not shown). Table I summarizes HPV-positive cases with respect to the anatomical tumour site and the various participating health care centres. Of note, with 12/95 (12.6%) HPV-positive SCC overall and 6/27 (22.2%) HPV-positive tonsillar SCC patients treated in health care centres with populations from metropolitan areas (Hamburg, Cologne; population >1 million) showed lower HPV prevalence rates than determined in patients treated in the other health care centres with study populations from rather rural areas (Greifswald, Rostock, Lübeck, Kiel, Oldenburg, Hanover; population <550.000). In the latter, HPV INK4A staining lacking HPV DNA signals were e6/e7-negative. From the HPV DNA-positive cases 62 (86.1%) were also HPV mRNA-positive and ten cases were HPV DNA-positive without e6/e7 mRNA signals. The latter cases must be assumed as being not HPV-driven. From these ten cases, four could be assigned to patients treated in Lübeck, two in Cologne, one in Hanover, Oldenburg, and Greifswald, respectively. Regarding the anatomical site of the primary tumour 57/59 (96.6%) HPV DNA-positive tonsillar SCC were HPV mRNA-positive and 5/13 (38.5%) of HPV DNA positive non-tonsillar SCC cases (oral cavity, n=3; oropharynx other than tonsils, n=1; hypopharynx, n=1), were HPV mRNApositive thus, classifying these cases as HPV-driven. no, weak, and moderate p16
INK4A expression in 50 (21.3%), 49 (20.9%), and 104 (44.3%) cases, respectively. In conclusion, for this specific study population in case of HPV DNA positivity only cases with strong diffuse immunohistochemical staining for p16 INK4A (+++) should be defined as p16 INK4A -positive in terms of representing a surrogate marker for HPV activity (Fig. 2) .
Presence of HPV DNA, E6/E7 mRNA expression and p16
INK4A expression, smoking habit and survival. Kaplan-meier calculations demonstrated statistically significant better PFS and OS rates for HPV DNA (p= 0.007 and p= 0.014, respectively) or HPV mRNA (p= 0.005 and p= 0.052, respectively) positive cases (Fig. 3) . Strong, moderate, weak and no p16 INK4A expression correlated with PFS (p<0.001) with cases strongly expressing p16 INK4A showing the longest survival times (Fig. 3) . Further Kaplan-meier calculations showed better PFS rates for HPV DNA and p16
INK4A
-positive cases in comparison to HPV DNA and p16
INK4A -negative cases (p= 0.007; HPV mRNA in combination with p16 INK4A expression, p=0.006). For these parameters, the significance was lost when focussing on OS (Fig. 4) . When analysing tonsillar and non-tonsillar SCC, out of 149 HPV DNA-negative non-tonsillar SCC cases 16 patients died within the observation time whereas all 11 patients with HPV DNA-positive non-tonsillar SCC are still alive. In comparison, out of 68 HPV DNA-negative tonsillar cases 9 patients died, whereas among the HPV DNA-positive cases of this group 1/48 patients died (p=0.03). Survival data solely stratified for smoking habit showed a significant survival advantage for non-smoking patients (p<0.001). When stratifying the HPV-positive and HPV-negative patients combined with smoking habit in any combination survival data did not show differences in the course of diseases.
Fisher's exact test demonstrated strong correlations between HPV DNA and p16 INK4A , HPV DNA and E6/E7 mRNA expression, and between p16
INK4A and E6/E7 mRNA expression (each p<0.001).
Discussion
The results of this unique study retrospectively investigating 307 HNSCC patients with tonsillar and non-tonsillar SCC living in various regions of mostly Northern Germany reveals that i) besides a considerable proportion of tonsillar SCC there is a certain, albeit smaller subgroup, of patients with nontonsillar SCC which is HPV-driven, ii) there is a significant diversity of HPV prevalence rates obviously solely depending on geographical influences, iii) p16
INK4A alone seems to be a stronger predictor of survival than HPV alone or even in combination with p16 INK4A immunohistochemistry. In the following these intriguing results will be discussed in more detail.
With 23.5% HPV DNA-positive cases overall and 44% positive tonsillar cases the detected prevalence rates in the total study population were within the range expected for a German population. The by far lower HPV prevalence rate in this study population when compared to for instance Scandinavian study populations with HPV prevalence rates up to 90% (13, 18) may be explained by the rather high proportion of smokers in our study population. It is well documented that in countries with successful anti-smoking campaigns the rise in incidence of HPV-related carcinomas is predominant. Focussing on the prevalence rates of the various cities in this study, the results show diversity in HPV prevalence of up to 60% (Table I) .
Analysing FFPE tissue specimens, HPV DNA-positive cases could be detected in 44% of tonsillar SCC and in 8% of non-tonsillar cases (Table I) . However, active HPV infections diagnosed by E6/E7 mRNA expression could only be detected in 38.5% of non-tonsillar SCC whereas 96.6% of tonsillar HPV DNA-positive SCC could be defined as HPV-driven. Hence, carcinogenic HPV infections in subsites outside the Waldeyers' tonsillar ring seem to be rather infrequent. These results are, thus, in agreement with other, specifically uS-American HPV prevalence studies not regularly detecting HPV infections in SCC outside the oropharynx (4, 24, 29, 30) . However, between 2005 and 2010, HPV DNA prevalence studies were performed in various study populations from Kiel (patients investigated overall, n=314) applying comparable detection methods as in the present study, yet, analysing fresh frozen tissue specimens (8, 9, 15, (31) (32) (33) (34) . The determined HPV prevalence rates in SCC from the Waldeyers' tonsillar ring, the oropharynx other than tonsils, oral cavity, larynx and hypopharynx were 56, 13, 28, 24 and 28%, respectively. moreover, in our recent study on the validity of p16 INK4A immunohistochemistry for the identification of active HPV infections in HNSCC we showed that i) the vast majority of tonsillar SCC contains active HPV infections ii) whereas the approximate rate is 50% of SCC of non-tonsillar origin (8, 9) . This diversity in HPV detection INK4A (e and F). The data demonstrate that p16 INK4A alone is a better predictive factor for progression-free survival than all other parameters tested. except for HPV DNA status all other parameters do not show significant differences for overall survival.
rates in the former and the present study and specifically the fact that the population of non-tonsillar SCC patients from Kiel investigated in the present study does not show any HPV infections at all leads us to assume that these variations predominantly are caused by the different material used for HPV detection, namely FFPe vs. fresh frozen.
HPV prevalence obviously is also influenced by geographical aspects. Certainly, the knowledge on varying HPV prevalence rates when investigating populations from different continents or countries is well established (4, 13, (16) (17) (18) (19) 35) . However, here we demonstrate for the first time that these differences in prevalence rates with variations up to 60% do also exist in different regions of close proximity (for details see legend to Table I ). We certainly assume that these variations are not caused by just the geographic region per se, but by variations in social aspects (smoking habit, alcohol consumption, education, income and so forth), and/or sexual behaviour triggered by the characteristics of the regions the patients live in. Due to the retrospective design of this study, parameters like alcohol consumption and sexual behaviour could not be evaluated reliably.
Survival analysis in the entire population demonstrated a statistical significant PFS and OS advantage for HPV DNA-positive cases (Fig. 3) with HPV DNA being the only parameter showing significant differences for OS. Although the survival benefit for HPV DNA-positive patients is very 
